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Summary
Patients with homozygous familial hypercholesterolaemia
are optimally treated with low-density lipoprotein
apheresis. Young patients who do not meet a weight
threshold (25 kg) receive regular plasmapheresis. This
approach may remove excessive immunoglobulins and
vascular access set-up can be challenging. We report the
case of a 4 year-old child who exhibited repeated septic
infections (5 in 6 months) and had recurrent access
issues before two interventions were implemented:
(1) the percutaneous central venous line was modified
to two implanted paediatric ports, and (2) the patient
started receiving two bags of Octaplasma at the end
of each plasmapheresis treatment to account for the
excessive loss of immunoglobulins. For the paediatric
plasmapheresis access port, a 19-gauge Huber needle
had to be used for the arterial port to prevent the
collapse of the extension. These two simple changes
have left the patient infection-free for 9 months.
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Familial hypercholesterolaemia (FH) is the result
of a mutation in a low-density lipoprotein (LDL)
receptor gene that presents as elevated plasma
LDL.1 The elevated LDL levels put patients at a
much higher risk of cardiovascular events and
early death.2 If both of the LDL receptor alleles
are abnormal, the patient will present with the
most severe version of the disease, homozygous FH
(HoFH); the severity of the condition depends on
the residual LDL receptor activity.1 The exceptionally high LDL levels seen in HoFH may be associated
with childhood death.3 Unlike heterozygous FH,
where lifestyle management and medications may
be enough to control plasma LDL levels, patients
with HoFH with minimal to no LDL receptor
activity require extracorporeal LDL removal.4
Although the treatment of choice for HoFH is
LDL apheresis,1 patients who do not meet the
weight threshold of 25 kg are treated with conventional plasmapheresis because it allows for a smaller
extracorporeal volume. The fundamental difference
between plasmapheresis and LDL apheresis is that
LDL apheresis specifically removes LDL, whereas
plasmapheresis removes all plasma components,
which must be replenished with a plasma product
such as 5% albumin. Still, regular plasmapheresis
removes all plasma including immunoglobulins and
other essential plasma components. The purpose

of this case report is to describe the measures that
were undertaken to reduce the number of plasmapheresis-related serious adverse events in a small
4-year-old girl with HoFH who was ineligible for
lipid apheresis.

Case presentation
We report the case of a child from consanguineous
parents of South Asian origin who shared the same
grandfather. A complete nonsense mutation of the
LDL receptor was identified in the patient shortly
after her birth. Her brother had been diagnosed
with the same condition and had passed away
from a cardiovascular event at 4 years of age. The
patient started her treatment at another centre
before relocating to London, Ontario. When her
LDL cholesterol level reached 24 mmol/L (reference interval <4 mmol/L) at this centre, she was
first treated with rosuvastatin, aspirin and ezetimibe. Unsurprisingly, this therapy was inadequate
in controlling her LDL cholesterol levels. She was
therefore started on plasmapheresis and received
numerous vascular access surgeries and suffered
infectious complications. Her family relocated to
London, Ontario in 2015. On examination, she
was found to be growing along the fourth percentile
for height. The physical was unremarkable except
for a small tendon xanthoma over her left elbow.
There were no xanthelasma, no corneal arcus
and no other xanthomas. She had a percutaneous
central venous line (dual-lumen permacath for
haemodialysis) for vascular access. She was treated
with plasmapheresis every 2 weeks, but her total
cholesterol rose to 15 mmol/L and her calculated
LDL rose to 14 mmol/L between the plasmapheresis
treatment sessions. The frequency of the treatments
was increased to weekly to achieve LDL concentrations <10 mmol/L between treatments.
Unfortunately, she developed multiple complications. A couple of weeks after her transfer, she
developed a Staphylococcus aureus line sepsis that
originated at her dual lumen permacath line. She
had to be admitted to the intensive care unit and
was treated with inotropic agents. Her recovery
was then complicated with the appearance of pneumonia. The line also migrated and had to be replaced
with a new percutaneous dual-lumen haemodialysis
catheter. Sixteen days later, she developed another
S. aureus catheter sepsis that required the complete
removal of all her vascular access for 3 weeks. A
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new percutaneous tunnelled haemodialysis catheter was then
inserted. Two months later, she developed another catheter
infection with gram-positive cocci. Following another catheter
change, she developed a severe Stenotrophomonas septicaemia;
she stayed in the critical care unit for some time and was treated
with inotropes. Stenotorophmonas infections have a mortality
rate of 40.6% and have a high rate of mortality in immunocompromised children.5 In the meantime, she was also diagnosed
with coeliac disease. At this point, she had 50 hospital visits,
including 4 admissions, 6 surgeries, 7 visits to the emergency
room and 24 plasmapheresis treatments in the 7 months since
her transfer from the other centre.

Treatment

The authors decided to implement two significant changes to the
patient’s treatment to address her complicated disease progression and to reduce her morbidity and risk of mortality. First,
her percutaneous central venous catheter was changed to an
implanted port. Second, her plasmapheresis treatments were
supplemented with two bags of detergent treated full plasma
(Octaplasma) rather than with 5% albumin to compensate for
the excessive loss of immunoglobulins.

Outcome and follow-up

When looking to change the port, the dual-chamber implanted
port we had on the hand was too large, and a single implanted
port would not allow the treatment team to draw from one
lumen and to push back through another. To further complicate the matter, there is no single-needle approach. We therefore decided to implant two single implanted paediatric ports.
After inserting the two single implanted paediatric ports, once
accessed, we connected the Huber needle extension tubing to
the plasmapheresis machine and tried to draw blood, only to
find that the combined strong negative pressure and softness
of the Huber needle extension tubing caused it to collapse.
We tried numerous brands of Huber needles but encountered
the same problem with each one. Although not power injectable implanted ports, we then opted to use a larger gauge,
power-injectable 19 gauge Huber needle. The plasmapheresis
was administered without the extensions collapsing when
this needle was used to access the ‘arterial’ port where the
blood was being drawn (figures 1 and 2a and b). Accessing
with a 20-gauge Power Injectable Huber needle functioned
well for the second or return implanted port.
The aim of the second arm of our approach addressed
the significant loss of immunoglobulins from plasmapheresis treatments. We infused the patient with 2 units of Octaplasma following each of her plasmapheresis sessions. On

Figure 1
gauge.
2

Figure 2 (A) Photo of vascular access using two single implanted
paediatric ports in our patient. (B) Photo of two single implanted
paediatric ports when not being accessed.
testing, her serum immunoglobulin levels increased from
2.1 to 4.2 g/L (normal range 4.5–11.5 g/L). She has not had
any infections in the 9 months that have passed as we implemented these two approaches. Considering that she had had
five major infections in the 6 months before these changes
were made, we would consider these changes successful.
Increasing the exchange plasma of the Optia plasmapheresis
machine to twice the volume would allow us to treat her
every 10 days. Going forward, we hope to convert her to
LDL apheresis when her weight reaches 25 kg.

Discussion

We report the case of a young patient with HoFH who has
suffered from numerous complications while receiving plasmapheresis treatments including recurrent line infections
and sepsis. Although LDL apheresis is the preferred method
for treating patients with HoFH,6 7 logistical problems such
as the patient’s size can limit its use. The primary hurdle a
practitioner will encounter when unable to treat a patient
with LDL apheresis is the limitation of the priming volume
of the apheresis equipment exceeds 15% of the blood volume
in children <25 kg. The required extracorporeal volume is
greater with commercially available LDL apheresis machines
than with modern plasmapheresis equipment such as the
Optia. Plasmapheresis is the second-best option once statin
and ezetimibe therapy have been exhausted. Unfortunately,
the non-specific immunoglobulin removal and access-related
issues associated with plasmapheresis resulted in serious
infectious complications in this preschool child.
Maintaining a viable access point in the patient was a major
challenge for the treatment team. Although central venous
lines are suitable for rapid fluid infusions such as those
required with plasmapheresis treatment, they are associated

Diagram of vascular access using two paediatric ports. The larger 19G needle is required for drawing the blood. 19G, 19 gauge; 20G, 20
Lee M, et al. BMJ Case Rep 2017. doi:10.1136/bcr-2017-219538

Learning from errors
with infection risks and have a 7.3% rate of septicaemia.8
Furthermore, plasma replacement itself is also a risk factor
for infections, and the rate of risk of a relapse infection may
exceed 50%. 9 With implanted ports, the infection risks can
be decreased. In our case, there were no technical or infectious complications during her follow-up of 9 months.
To add to this, high negative arterial pressure is created by
the plasmapheresis machine when it draws blood from the
patient. This pressure can deform and collapse the blood
pump-segment tubing. According to the Hagen-Poiseuille
law, a larger tube diameter creates less pressure. Studies in
patients on haemodialysis have also demonstrated that larger
gauge needles can significantly increase the rate of blood
flow delivered by the dialysis machine. 10 We applied these
principles from adult patients on haemodialysis and found
that they also apply for children. Using a larger 19-gauge
arterial port Huber needle in our patient prevented the
extensions from collapsing and produced effective blood
flow rates.
Plasmapheresis also caused hypogammaglobulinaemia in
our patient. Unlike LDL apheresis, which selectively removes
LDL from plasma while preserving other components, plasmapheresis replaces the entire plasma, lowering cardioprotective components and immunoglobulin levels. Removing
immunoglobulins with each plasmapheresis treatment can
induce immunosuppression. 11 This unintended aftereffect
precipitated the numerous central line infections and the
sepsis that occurred in our young patient. Infusions with
intravenous immunoglobulin and Octaplasma compensated
for the patient’s decreased number of immunoglobulins
and may have contributed to the reduced rate of infection.
Previous studies have shown that prophylactic intravenous immunoglobulin replacement therapy can modulate
hypogammaglobulinaemia and potentially decrease the
incidence of severe infections. 12 Unfortunately, immunoglobulin supplementation is costly. One 1 g/kg intravenous immunoglobulin treatment costs approximately CAD
$4200, while one plasma exchange treatment consisting
of 1.0 plasma volume exchange with 5% albumin replacement fluid costs approximately CAD $1300. 13 These additional costs must of course be weighed against the hospital
admission costs associated with serious and life-threatening
complications such as repeated episodes of catheter sepsis.
Luckily in Canada, these costs are absorbed by the Canadian Blood Services and blood products are given to the
hospitals for free. The blood bank of the hospital followed
our line of thought and approved the use of Octaplasma
until the patient reaches the appropriate weight for LDL
apheresis.
In summary, our 4-year-old patient with HoFH received
regular plasmapheresis treatments and as a result suffered
from numerous access problems and infections; her complications subsequently improved with the insertion of two
implanted paediatric ports and with Octaplasma supplementation. Through a process of trial and error, we learnt that a
19-gauge power injectable Huber needle is best for accessing
the arterial port when a paediatric patient is receiving plasmapheresis through paediatric ports. Implementing these
types of interventions can help physicians control recurring
infections in similar patients.
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Learning points
►► Infections and access problems may pose a problem in small

children with homozygous familial hypercholesterolaemia
who are receiving plasmapheresis treatments.
►► Initiating Octaplasma supplementation following each
plasmapheresis session can decrease infection rates.
►► Two single implanted paediatric ports may be the ideal choice
for a small child with recurring access-related complications.
►► A large 19-gauge power injectable Huber needle should be
used to access the patient’s ‘arterial’ port in order to prevent
the soft extension from collapsing when paediatric ports are
used to administer plasmapheresis.
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